Selective activation of adenosine A3 receptors with N6-(3- chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via K(ATP) channel activation

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 138-145

  Tracey, W Ross ^a   Magee, William ^a   Masamune, Hiroko ^a   Oleynek, Joseph J ^a   Hill, Roger J ^a  

^a PFIZER INC   (United States)

Author keywords

Adenosine; Heart; Infarction; K(ATP) channel; Preconditioning; Rabbit; Receptors; Reperfusion

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; N6 (3 CHLOROBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ADENOSINE; ADENYLATE CYCLASE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CYCLIC AMP; DECANOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GLYBURIDE; HYDROXY ACIDS; HYPOGLYCEMIC AGENTS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERFUSION; POTASSIUM CHANNELS; RABBITS; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; XANTHINES;

EID: 0032190313     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00112-6     Document Type: Article

References (44)

1. [1] Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
2. [2] Ely SW, Mentzer RM, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985;90:549-556.
3. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
4. 1-selective adenosine analogues protects the heart against infarction. Circulation 1992;85:659-665.
5. [5] Liu GS, Richards SC, Olsson RA, et al. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-1061.
6. 6-cyclopentyladenosine (CCPA) causes a sustained limitation of infarct size in rabbits. Cardiovasc Res 1993;27:652-656.
7. 3-receptor involvement. Cardiovasc Res 1994;28:1049-1056.
8. 1-receptor agonist, R(-)N(2-phenylisopropyl)-adenosine (PIA), but not adenosine itself, acts as a therapeutic preconditioning-mimetic agent in rabbits. Cardiovasc Res 1993;27:2140-2145.
9. 1-receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol 1990;22:39-47.
10. 3-receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33:410-415.
11. 6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80:800-809.
12. 3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320:241-248.
13. 3 receptors during prolonged simulated ischemia. Am J Physiol 1997;273:H501-H505.
14. 3 receptors. J Clin Invest 1996;98:1773-1779.
15. [15] Grover GJ, Sleph PG, Dzwonczyk S. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs. J Cardiovasc Pharmacol 1990;16:853-864.
16. [16] Rohmann S, Fuchs C, Schelling P. In swine myocardium, the infarct size reduction by U-89232 is glibenclamide sensitive: evidence that U-89232 is a cardioselective opener of ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1997;29:69-74.
17. [17] Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium-channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995;92:1236-1245.
18. [18] Grover GJ, McCullough JR, Henry DE, Condor ML, Sleph PG. Antiischemic effects of the potassium-channel activators pinacidil and cromakalim and the reversal of these effects with the potassium-channel blocker glyburide. J Pharmacol Exp Ther 1989;251:96-104.
19. [19] McCullough JR, Normandin DE, Conder ML, et al. Specific block of the antiischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69:949-958.
20. [20] Grover GJ, Parham CS, Whigan DB, Mitroka JG. BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances post-ischemic recovery of contractile function in dogs. J Pharmacol Exp Ther 1996;276:380-387.
21. [21] Hide EJ, Thiemermann C. Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. Cardiovasc Res 1996;31:941-946.
22. ATP-channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res 1994;28:1337-1341.
23. [23] Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993;27:617-622.
24. [24] Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic preconditioning in dogs by the novel ATP-dependent potassium-channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992;26:1054-1062.
25. [25] Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-233.
26. +-channel blocker. Circulation 1994;90:700-705.
27. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77:1030-1035.
28. 1-receptors. Circulation 1992;86:1310-1316.
29. ATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993;264:H1327-H1336.
30. ATP channel. Am J Physiol 1994;266:H829-H839.
31. [31] Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Ann Rev Pharmacol Toxicol 1995;35:581-606.
32. 3 receptors. J Pharmacol Exp Ther 1997;280:122-128.
33. 3-selective adenosine agonists. J Med Chem 1994;37:636-646.
34. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
35. + channel. J Mol Cell Cardiol 1997;29:175-182.
36. [36] Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J. Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP-sensitive potassium channels. Cardiovasc Res 1993;27:623-629.
37. ATP channels. Circulation 1994;89:1229-1236.
38. 1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990;259:H820-H826.
39. + channels. A possible mechanistic link to ischemic preconditioning. Cardiovasc Res 1996;79:399-406.
40. ATP channel. Am J Physiol 1997;273:H847-H853.
41. + channels. J Biol Chem 1988;263:7933-7936.
42. + channel by 5-hydroxydecanoate in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1992;260:702-708.
43. [43] Niho T, Notsu T, Ishikawa H, et al. Study of mechanisms and effects of sodium 5-hydroxydecanoate on experimental ischemic ventricular arrhythmia. Folia Pharmacol Jpn 1987;89:155-167.
44. + currents in pancreatic β cells. Naunyn-Schmiedeberg's Arch Pharmacol 1988;337:225-230.